Histological and histomorphometrical evaluation of two types of bone substitutes in combination with i-PRF for bone regeneration in critical bone defects: An in vivo study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Aim This study aimed to evaluate the bone regeneration performance of two types of xenografts (Bio-Oss, Geistlich Pharma AG, Wolhusen, CH; Cerabone, Institut Straumann, Basel CH) isolated and associated with i-PRF, in critical bone defects in rat calvaria.
Materials and methods Surgical defects were performed and filled with different materials, according to the referred groups: clot (CG), autogenous bone (AG), Bio-Oss® (BO), Cerabone (CB), i-PRF homogenous (i-PRF), Bio-Oss associated with i-PRF (BOPRF) and Cerabone associated with i-PRF (CBPRF). The animals were euthanized for histological and histomorphometric analysis after 4 and 8 weeks. Statistical analysis for bone neoformation assessment was performed by ANOVA and complemented by Tukey's test.
Results The AG group exhibited the highest mean values for bone neoformation (37.83 ± 7.96) in this study. Among the bone substitutes, CBPRF group (18.79 ± 5.98) exhibited highest means (p<0.05) compared to BO group (10.20 ± 2.82) and CG group (6.96 ± 3.29). i-PRF group (17.07 ± 4.95), BOPRF group (16.86 ± 6.14), BO group (10.20 ± 2.82), and CB group (16.15 ± 4.72) were not significant among them (p>0.05).
Conclusions According to the results obtained in this study, it was observed that Cerabone® and Bio-Oss®, associated with i-PRF, exhibited a satisfactory applicability to fill critical defects, favoring the bone regeneration process.
Copyright (c) 2022 Ariesdue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Journal of Osseointegration has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.